{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:46:27Z","timestamp":1790181987803,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Sympathetic overactivity and high levels of the endogenous inhibitor of NO synthase asymmetric dimethylarginine (ADMA) are prevalent risk factors in chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>In 48 stage 2 to 4 CKD patients, we investigated the relationship between efferent postganglionic muscle sympathetic nerve traffic (microneurography) and circulating ADMA and analyzed the links between these risk factors and estimated GFR (eGFR), proteinuria, and different parameters of left ventricular (LV) geometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CKD patients characterized by sympathetic nerve traffic values in the third tertile showed the highest ADMA levels, and this association was paralleled by a continuous, positive relationship between these two risk factors (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.32,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03) independent of other confounders. Both sympathetic nerve traffic and ADMA were inversely related to eGFR and directly to proteinuria and LV geometry. Remarkably, the variance of eGFR, proteinuria, and LV geometry explained by sympathetic nerve traffic and ADMA largely overlapped because sympathetic nerve traffic but not ADMA was retained as a significant correlate of the eGFR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and of the relative wall thickness or the left ventricular mass index\/LV volume ratio (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.05) in models including both risk factors. ADMA, but not sympathetic nerve traffic, emerged as an independent correlate of proteinuria (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003) in a model including the same covariates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sympathetic activity and ADMA may share a pathway leading to renal disease progression, proteinuria, and LV concentric remodeling in CKD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.06970711","type":"journal-article","created":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T21:34:23Z","timestamp":1316727263000},"page":"2620-2627","source":"Crossref","is-referenced-by-count":54,"title":["Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease"],"prefix":"10.2215","volume":"6","author":[{"given":"Guido","family":"Grassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Seravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ghiadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20230811","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2458-8-117","article-title":"Prevalence of chronic kidney disease in population-based studies: Systematic review","volume":"8","author":"Zhang","year":"2008","journal-title":"BMC Public Health"},{"key":"R2-12-20230811","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(00)02456-9","article-title":"Premature cardiovascular disease in chronic renal failure","volume":"356","author":"Baigent","year":"2000","journal-title":"Lancet"},{"key":"R3-12-20230811","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.ki.5000417","article-title":"Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective","volume":"70","author":"Zoccali","year":"2006","journal-title":"Kidney Int"},{"key":"R4-12-20230811","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1523-1755.2004.00552.x","article-title":"Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment","volume":"65","author":"Neumann","year":"2004","journal-title":"Kidney Int"},{"key":"R5-12-20230811","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/ajh.2010.154","article-title":"Sympathetic neural activity in hypertension and related diseases","volume":"23","author":"Grassi","year":"2010","journal-title":"Am J Hypertens"},{"key":"R6-12-20230811","first-page":"14","article-title":"The sympathetic nervous system and the kidney: Its importance in renal diseases","volume":"3","author":"Ritz","year":"1998","journal-title":"Blood Press Suppl"},{"key":"R7-12-20230811","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2005.05.009","article-title":"Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age?","volume":"46","author":"Kielstein","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R8-12-20230811","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.ASN.0000106717.58091.F6","article-title":"Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease","volume":"15","author":"Mallamaci","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R9-12-20230811","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0735-1097(01)01786-7","article-title":"Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation","volume":"39","author":"Hijmering","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R10-12-20230811","doi-asserted-by":"crossref","first-page":"R726","DOI":"10.1152\/ajpregu.00768.2004","article-title":"L-NAME- and ADMA-induced sympathetic neural activation in conscious rats","volume":"290","author":"Augustyniak","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R11-12-20230811","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Tarazi","year":"1992","journal-title":"N Engl J Med"},{"key":"R12-12-20230811","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1681\/ASN.V12112427","article-title":"Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension","volume":"12","author":"Klein","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R13-12-20230811","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","article-title":"Sympathetic nerve activity in end-stage renal disease","volume":"106","author":"Hausberg","year":"2002","journal-title":"Circulation"},{"key":"R14-12-20230811","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1097\/01.ASN.0000098687.01005.A5","article-title":"Sympathetic nerve activity is inappropriately increased in chronic renal disease","volume":"14","author":"Klein","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R15-12-20230811","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1152\/japplphysiol.90849.2008","article-title":"Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease","volume":"105","author":"Park","year":"2008","journal-title":"J Appl Physiol"},{"key":"R16-12-20230811","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.110.164780","article-title":"Early sympathetic activation in the initial clinical stages of chronic renal failure","volume":"57","author":"Grassi","year":"2011","journal-title":"Hypertension"},{"key":"R17-12-20230811","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.HYP.0000022063.50739.60","article-title":"Norepinephrine and concentric hypertrophy in patients with end-stage renal disease","volume":"40","author":"Zoccali","year":"2002","journal-title":"Hypertension"},{"key":"R18-12-20230811","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-1755.2002.00437.x","article-title":"Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients","volume":"62","author":"Zoccali","year":"2002","journal-title":"Kidney Int"},{"key":"R19-12-20230811","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1515\/CCLM.2004.257","article-title":"Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay","volume":"42","author":"Schulze","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"R20-12-20230811","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","article-title":"Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method","volume":"55","author":"Devereux","year":"1977","journal-title":"Circulation"},{"key":"R21-12-20230811","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1681\/ASN.V5122024","article-title":"The prognostic importance of left ventricular geometry in uremic cardiomyopathy","volume":"5","author":"Foley","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R22-12-20230811","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1176\/appi.ajp.158.6.848","article-title":"How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors","volume":"158","author":"Kraemer","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R23-12-20230811","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/MNH.0b013e328314b6ca","article-title":"Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease","volume":"17","author":"Kielstein","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R24-12-20230811","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2005010076","article-title":"Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach","volume":"16","author":"Ravani","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R25-12-20230811","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1681\/ASN.2005020179","article-title":"Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study","volume":"16","author":"Fliser","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R26-12-20230811","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/HJH.0b013e32832b521b","article-title":"Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?","volume":"27","author":"Siddiqi","year":"2009","journal-title":"J Hypertens"},{"key":"R27-12-20230811","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1046\/j.1523-1755.2001.00936.x","article-title":"Glomerulosclerosis and progression: Effect of subantihypertensive doses of alpha and beta blockers","volume":"60","author":"Amann","year":"2001","journal-title":"Kidney Int"},{"key":"R28-12-20230811","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.2007050552","article-title":"Autonomic renal denervation ameliorates experimental glomerulonephritis","volume":"19","author":"Veelken","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R29-12-20230811","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000313927","article-title":"Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis","volume":"32","author":"Chen","year":"2010","journal-title":"Am J Nephrol"},{"key":"R30-12-20230811","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM199904293401704","article-title":"Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure","volume":"340","author":"Ligtenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"R31-12-20230811","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.ASN.0000045049.72965.B7","article-title":"Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure","volume":"14","author":"Klein","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R32-12-20230811","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1093\/ndt\/gfq159","article-title":"Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA: A novel pathophysiological pathway?","volume":"25","author":"Yilmaz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R33-12-20230811","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/CIRCULATIONAHA.106.668863","article-title":"Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension","volume":"115","author":"Burns","year":"2007","journal-title":"Circulation"},{"key":"R34-12-20230811","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/ndt\/gfq175","article-title":"Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment","volume":"25","author":"Siddiqi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R35-12-20230811","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ejim.2010.07.001","article-title":"Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease","volume":"21","author":"Shi","year":"2010","journal-title":"Eur J Intern Med"},{"key":"R36-12-20230811","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.CIR.0000137831.08683.E1","article-title":"Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice","volume":"110","author":"Liao","year":"2004","journal-title":"Circulation"},{"key":"R37-12-20230811","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0b013e31817e0edd","article-title":"Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure","volume":"52","author":"Alfieri","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"R38-12-20230811","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201111000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:21Z","timestamp":1786369281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201111000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.06970711","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}